1 Lab Ofichem B.V. Pag.: 1 / 14 Date: Version: 02 Status: geldig Contents 1. General Shared Third Party audit program Reassurance absence of Conflict of Interest Contract structure The auditor Educational Background and Experience Auditor Training Course for Certification Responsibilities The auditing process Request for an audit Preliminary Inventarisation Audit Contract Preparation of the audit Execution of the audit The audit report Resolution of disagreement with GMP deficiencies or performance of the auditor Audit Follow Up Costs Considerations Other additional services Annex 1 Audit Contract Date Paraph Distribution Author General Management Quality Assurance
2 Lab Ofichem B.V. Pag.: 2 / 14 Date: Version: 02 Status: geldig 1. General According to the EU legislation the following is valid: the holder of a manufacturing authorization shall at least be obliged to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting materials (Directive 2001/83/EC as amended, article 46(f) for Human Medicinal Products and Directive 2001/82/EC, Article 50(f) for Veterinary Medicinal Products). Both the Document entitled Guidance on the occasions when it is appropriate for Competent Authorities to conduct inspections at the premises of manufacturers of active substances used as starting materials (1) and also the EMA Website GMP Question and Answers on audits of active substances manufacturers ( give further guidance on what the European Authorities expect in terms of assessing the GMP status of active substance manufacturers. An audit conducted by or done on behalf of the Manufacturing Authorisation Holder (MAH) of their manufacturers or suppliers of the Active Pharmaceutical Ingredient (API) should be an integral part of the Supplier Qualification Procedure of the MAH. Audits should be performed by qualified, trained and well experienced auditors. The audit should be properly documented and the audit reports will be subject to inspection by the Competent Authorities during inspections of the MAH for the Medicinal Products. Audits should be done periodically (every 2 to 3 years) to assess the continuing GMP Compliance status of the API Manufacturer and, if necessary, other companies in the supply chain such as an intermediate company, an Agent, a Broker, a Packer, a Re-Packer, a Distributor or a Importer of the API. A MAH can conduct audits herself or assign a Third Party to perform the audit. If a Third Party is involved then the MAH, as contract giver, should follow Chapter 7 of the EU GMP Guide and evaluate the Third Party auditors and audit process (as the contract acceptor ) to ensure that the audit process complies with their GMP expectations. The MAH should ensure there is no conflict of interest between the audit process, the auditors and the Auditee. Several options for performing an audit are acceptable for the European Authorities: A Second Party Audit of the API manufacturer performed by the Qualified Auditors of the MAH. A Third Party Audit of the API Manufacturer performed on behalf of the QP of the MAH. The QP of the MAH (Contract Giver) confirms that the Audit Process of the contract acceptor provides an effective assessment of the GMP status of the API manufacturer and that the audit is performed by independent, qualified auditors with no conflict of interest. Shared Third Party Audits are acceptable to the European Authorities as long as the QP ensures that the scope of the audit is applicable to each Medicinal Product that uses the API as Starting Material. In the opinion of the Ad Hoc GMP Inspection Services meeting of EU Inspectors organized by EMA, it was decided that MAH should evaluate for themselves whether a possible conflict of interest could occur with any Third Party Audit option.
3 Lab Ofichem B.V. Pag.: 3 / 14 Date: Version: 02 Status: geldig 2. Scope Description of the Lab Ofichem shared third party program. 3. Definitions and abbreviations ASMF Active Substance Master File API Active Pharmaceutical ingredient DMF Drug Master File MAH Manufacturing Authorization Holder GMP Good Manufacturing Process QP Qualified Person EMA European Medicine Agency QA Quality Assurance 4. Shared Third Party audit program The approach performed by many Drug Product Manufacturers towards the legal requirement of auditing is to perform one to one audits of their API manufacturers. However, it is recognized that audits are timeconsuming and expensive for both the API and Medicinal Product Manufacturer. There is a potential risk for significant audit overload (so called audit fatigue ) in the Pharmaceutical Industry if this is the only option used. Consequently, it often appears that a Drug Product Manufacturer is not even welcome to perform an audit, especially if relative low quantities are purchased. The aim of the Shared Third Party audit program of Laboratorium Ofichem BV (Lab Ofichem) is to provide a standardized (Shared) Third Party Auditing process to ensure that an effective assessment is performed of the GMP status of APIs used as Starting Materials for Medicinal Products. Lab Ofichem operates as a contract audit organization in this matter (contract acceptor). The audits within the framework of the Shared Third Party audit program are conducted by Lab Ofichems Certified Auditors. Standardized reports with classification of findings are issued. Third Party Audits should be initiated by the MAH for the Medicinal product according the European directive 2001/83/EC and its amendments, in which it is defined that the MAH has the responsibility for assuring that the API is manufactured in accordance with the GMP in force. In case several MAHs wish to cooperate on an audit of the same API Manufacturer or share an audit report, the Third party audit becomes a Shared Third Party Audit. There are several distinct advantages of shared audits: 1. For the API manufacturer. A joined audit for several customers will be performed at once, which is much more interesting for the API manufacturer than one to one audits. 2. For the MAH. Performing audits is very time and cost consuming. Both can be saved in such an approach. Especially for the products that are not on the top of the priority list to be inspected. 3. For Lab Ofichem. In such a way an intensive partnership with both the API suppliers and the MAH can be build up and maintained. All the audits reports, request for audits and any other information are kept strictly confidential. A more detailed description of the process of shared party audits by Lab Ofichem is given in Chapter 4. The Lab Ofichem Auditing documentation provides the framework for the standardized audit program. Trained auditors follow the principles defined in the auditing guide, to ensure that the GMP status (ICH Q7) of each API manufacturer is assessed.
4 Lab Ofichem B.V. Pag.: 4 / 14 Date: Version: 02 Status: geldig The audit report will include descriptions of all subjects covered during the audit. Objective evidence for GMP deficiencies observed during the audit will be included in the report and such deficiencies will be classified by the auditors (classification rating; see table 1). Critical A deficiency which has produced, or leads to a significant risk of producing, either a product which is harmful to the human or veterinary patient or a product which could result in a harmful residue in a food producing animal. Examples: Cross contamination; Contaminants/microbiological contamination of sterile products; Deviations/changes (with consequences that are harmful to health or life-threatening); Contamination with serious medical consequences (solvents, pesticides); Defect/deficiency that represents an offence requiring intervention by the authorities; Significant deviations in the content of the quality documentation; Iterated appearance of major deviations. Major Other A non-critical deficiency, which has produced or may produce a product, that does not comply with its marketing authorization; or which indicates a major deviation from EU Good Manufacturing Practice; or which indicates a failure to carry out satisfactory procedures for release of batches; or a combination of several other deficiencies, none of which on their own may be major, but which may together represent a major deficiency and should be explained and reported as such. Examples: Significant non-compliance with the GMP rules or significant deviations from the GMP Guidelines; Inadequate discharge of the responsibilities of specialists from Quality Assurance; Significant deviations of the product from the DMF/ASMF content and or prior set specifications; Deviations that may result in residues that are harmful to health (Critical/Major, depending on the substance and therefore the risk). A deficiency, which cannot be classified as either critical or major, but which indicates a departure from good manufacturing practice. (A deficiency may be other either because it is judged as minor, or because there is insufficient information to classify it as a major or critical). Examples: Non-conformance to the GMP rules or deviations from the GMP Guidelines; Deviations of production and testing from the DMF/ASMF; Deviations and changes; Missing documentation for processes proven to be correct. Table 1: Classification of deficiencies.
5 Lab Ofichem B.V. Pag.: 5 / 14 Date: Version: 02 Status: geldig 5. Reassurance absence of Conflict of Interest Ofichem BV is a known trader in the veterinary segment of the pharmaceutical industry. A Shared Third Party audit program of a trader generally evokes the idea of a conflict of interest. In the pharmaceutical industry conflicts of interest are generally solved by a company structure with an independent QA department, whereas the general direction commits to respect the QA decisions. Lab Ofichem is a European GMP certified API manufacturer with an independent QA department. This Shared Third Party audit program is part of the responsibility of the QA department of Lab Ofichem. As such the absence of a conflict of interest can be reassured. Lab Ofichem is not interested in the gathering of approval reports to sell with the trading products of Ofichem. The structure of this shared third party audit program will not allow such practices. Lab Ofichem is interested in shared third party audits of the starting materials, while simultaneously the synergy between companies of the Ofichem-group provides the opportunity (knowledge of manufacturing APIs, awareness of many interested customers) to maintain a Shared Third Party audit program. 6. Contract structure A third party auditing company is in essence a contract auditor, that is contracted by the MAH (as described in chapter 7 of the EU GMP guidance). Therefore Lab Ofichem acts as a contract acceptor. The QP/Responsible Person of the MAH is the contract giver. A standard contract is presented in annex 1. Being a contract acceptor, all information about contract givers are handled strictly confidential. Information about participation is not shared with any other (participating) parties. The contract (see annex 1) includes this topic and ensures confidentiality. 1 Lab Ofichem is willing to be inspected by all contract givers and by all (inter)national authorities, if necessary. 1 The auditee is not part of the contract (e.g. to ensure confidentiality), since the API manufacturers in China are commonly known to be reluctant to sign an English contract before the audit starts. With the API manufacturer a bilingual secrecy agreement between Lab Ofichem and auditee is used.
6 Lab Ofichem B.V. Pag.: 6 / 14 Date: Version: 02 Status: geldig 7. The auditor An auditor is only qualified for performing the Shared Third Party audits if: the auditor has a particular educational background and/or experience, and the auditor is certified according to the APIC training course for auditors Educational Background and Experience The auditors should have a good educational knowledge of Pharmaceuticals and Chemistry. Qualifications as Pharmacist, Medical Doctor, Chemical Engineer, MSc or Ph.D. in Pharmacy, Chemistry, Biology or related fields as Agrochemistry etc., are appropriate. A good understanding of biochemistry and analytical techniques and practices is a definite advantage. At least 5 years practical experience (relevant function) in manufacturing of Active Pharmaceutical Ingredients under GMP conditions may also be considered as sufficient knowledge and background. The auditor must have a good knowledge of English Language, and preferably of the Chinese language Auditor Training Course for Certification Attendance at a specific five-day APIC training course (two and a half days related to GMP in API manufacturing and two and a half days for training in effective auditing techniques), including subsequent examinations is a requisite for becoming a Lab Ofichem Certified Auditor Responsibilities The auditor is an employee of the Quality Assurance Department of Lab Ofichem and will therefore operate under the responsibility of the Head of the department.
7 Lab Ofichem B.V. Pag.: 7 / 14 Date: Version: 02 Status: geldig 8. The auditing process The Following Section describes the steps that are followed in the audit process from the initial contact until the distribution of the audit report and the follow up (see figure 1). Initiation by Customer Initiation by Ofichem Request for an Audit (See 8.1) Selfassesment Audit Preliminary Inventarisation Signing of Audit Contract (See 8.2) Preparation for the Audit (See 8.3) Execution of the Audit (See 8.4) Audit Report (See 8.5) Audit Follow Up (See 8.6) Figure 1: The auditing process.
8 Lab Ofichem B.V. Pag.: 8 / 14 Date: Version: 02 Status: geldig 8.1. Request for an audit There are three possibilities for an audit request. 1. Initiation by Lab Ofichem 2. Initiation by one or more QP(s)/Responsible Person(s) of MAH(s) 3. Initiation for a self-assesment A request to initiate an audit should be made to the Quality Assurance Department of Lab Ofichem 8.2. Preliminary Inventarisation Preliminary to conducting an audit, Lab Ofichem will collect information and agree with each MAH on the following topics: Scope of the audit (EU GMP, US cgmp, oral, parenteral, etc.) Steps of the audit process Corrective Actions and Preventive Actions of previous audit Expected time inputs and expected costs Sample of an audit report, if desired Timetable Next, Lab Ofichem will contact all other customers that purchased any API of the selected auditee the last 2 years. Lab Ofichem will send them a standardized letter. In this letter Lab Ofichem will ask the customers if they want to join the audit. If any customer wants to join, Lab Ofichem will have the same preliminary inventarisation with that customer as with the original initiator. Obviously, all information will be kept strictly confidential. Potentially interested MAHs, will not be aware if other MAHs or how many MAHs, are interested in conducting the audit Audit Contract After the Preliminary inventarisation, Lab Ofichem will set up an audit contract (See annex 1). This audit contract has to be signed by the QP/Responsible Person of the MAHs and by the head of the QA department of Lab Ofichem. Contracts with each QP/Responsible Person will be documented separately.
9 Lab Ofichem B.V. Pag.: 9 / 14 Date: Version: 02 Status: geldig 8.4. Preparation of the audit Innitially the auditee is contacted and requested to provide relevant and available information for the audit (e.g. Site Master File, pre-audit questionnaire, etc.) Execution of the audit As a guideline, the audit will be performed by one auditor for two days. The customer has the responsibility to define the duration of the audit and the number of auditors if it is judged that more or less time or auditors are required to meet their requirements depending on the scope of the audit. Before the audit, the customer(s) and the auditee will receive an audit plan from the auditor(s), detailing the major topics of the audit and a tentative schedule. Agreement must be reached on the proposed audit plan from all parties involved (customer(s), auditee and auditor) before the audit can take place. During the audit the GMP compliance of the auditee will be evaluated by the auditors on the basis of the relevant GMP guidelines. All observations relating the GMP deficiencies will be explained, clarified and classified (see section 2 for the classification rating) during the final wrap up meeting with the Senior Management of the auditee The audit report At the latest, within a period of one month after the audit, the auditor sends an audit report to the auditee. The audit report will include a management summary and an overview of which ICH topics were evaluated during the audit. The auditee should check the accuracy and respond to any observations, proposing corrective actions, responsibilities and time frames within one month. On receipt of the audit report from the auditee, the auditor will review and confirm that a response with realistic timelines has been received for each observation, sign the audit report and make copy s for the auditee and the customer(s) within one month. The total process (audit, audit report, response auditee, evaluation auditor) will take approximately three months. The original audit report remains valid for 3 years and will be archived for an additional 5 years by Lab Ofichem. The customer(s) has/have the responsibility to review the signed audit report and decide if deficiencies have been adequately addressed. The evaluation of the impact of the audit deficiencies on the GMP status of the API(s) used in the Manufacture of Medicinal Products is the responsibility of the QP/Responsible Person of MAH(s) Resolution of disagreement with GMP deficiencies or performance of the auditor In case the QP/Responsible Person of the MAH is not satisfied with the Quality of the audit report or with the performance of the auditor, the QP/Responsible Person should contact Lab Ofichem in writing and explain their concerns. Lab Ofichem will review the concerns with the auditor and will try to come to a mutual satisfactory solution.
10 Lab Ofichem B.V. Pag.: 10 / 14 Date: Version: 02 Status: geldig 9. Audit Follow Up Following completion and issue of the audit report, the auditee should issue periodic updates on progress with proposed actions to Lab Ofichem based on the timelines defined in the audit report. Lab Ofichem will check if the proposed actions of the auditee in response to the audit observations have been implemented in a timely and effective manner. Once in the three years Lab Ofichem will do a follow up audit including auditing of the effectiveness of the corrective actions defined in the original audit report. If Lab Ofichem is going to perform a follow up audit all customer(s) will be informed and preliminary inventarisation and the rest of the program will be started again. 10. Costs Considerations The costs for participation depends partly on the amount of participators. The following aspects are considered: Audit: 900,-/day (includes preparation) Audit report and follow-up (CAPA review, etc.): 1000,- Travelling expenses: 400,- (estimation of mean expenses) (for audits in China, if audits are performed in another country prices will increase.). The costs for each participant are provided in table 2. No. of participants Costs Comment ,- On request 1 day audit 2300, , ,- >3 800,- Table 2: Costs per audit, depending on the number of participants. In all cases the statutory value added tax will be added.
11 Lab Ofichem B.V. Pag.: 11 / 14 Date: Version: 02 Status: geldig 11. Other additional services Lab Ofichem intends to maintain a database of worthy, compliant manufacturers, based on the information gathered with the presented Shared Third Party audit program. On request, several other services can be provided (see table 3): Assistance with supplier selection; Assistance (organizing, accompanying, translating) to your companies second party audits; Third party audit of manufacturer of non-gmp raw materials or intermediates against appropriate standards (ISO 9001, ICH Q7); Third party audits of distributors, traders, brokers and re-labelers according to appropriate standards (GDP, ICH Q7); Third party audit (not shared) on the shortest term possible, in case of regulatory pressure. Manufacturer of non-gmp raw material Manufacturer of API intermediate Manufacturer of finished API Distributors Marketing authorization holder Major standards of compliance ISO 9001 ICH-Q7 EU GMP (II) ICH-Q7 EU GMP (II) ICH-Q1, 2, 3, 6, 9, 10, 11 GDP EU GMP (I) or 21CFR210-1 ICH-Q1, 2, 3, 8, 9, 10 Common problems (1)Inefficient implementation of ISO 9001 principles. (1) Lack of awareness of requirement to comply with GMP; (2) Product insufficiently defined in terms of purity (3) Production moved or subcontracted for economical or environmental reasons, without notification to customer. (1) Gaps in GMP compliance; (2) Lack of awareness of ICH-Q2, Q3 & Q11 requirements; (3) Undeclared subsourcing and repackaging of API. (1) Lack of transparency; (2)Weak sourcing and monitoring of suppliers; (3) Repackaging of API from undeclared sources. (1)Weak sourcing practice; (2) Cost and complexity of supplier audits. What can be done Including the key raw materials in the GMP audit of the API Including the intermediate in the GMP audit of the API Audit of GMP compliance and manufacturing capacity GDP audit Sourcing services Auditing services
12 Lab Ofichem B.V. Pag.: 12 / 14 Date: Version: 02 Status: geldig Table 3: Potential opportunities and services. Annex 1 Audit Contract Agreement on Audit Execution and Secrecy between <name of company/mah> a company organized and existing pursuant to the laws of <country company/mah>, having its principal place of business at <address company/mah>, hereinafter referred to as Customer and Laboratorium Ofichem B.V. a company organized and existing pursuant to the laws of The Netherlands, having its principal place of business at Heembadweg 5, Ter Apel, The Netherlands, hereinafter referred to as Lab Ofichem
13 Lab Ofichem B.V. Pag.: 13 / 14 Date: Version: 02 Status: geldig 1. Subject of the Agreement Lab Ofichem will conduct audits on behalf of the Customer, after mutual agreement on auditee(s), drug substance(s), duration, scope and costs of the audit. The audits will be performed by a qualified and APIC certified auditor in order to verify the degree of compliance of the auditee with the ICH Q7 Guide GMP for APIs. 2. The Audit The audit date will be arranged between Lab Ofichem and the auditee. Any deficiencies found during the audit will be classified by the auditor and reported in the closing meeting of the audit. 3. Audit Report The audit report prepared by the auditor will give objective evidence of any GMP deficiencies found during the audit and each deficiency will be classified. A copy of the audit report will be sent to the auditee no later than one month after completion of the audit. The auditee is asked to check on accuracy and respond to any deficiencies within one month. The auditor will review and confirm that a response with realistic timelines is received for each observation. The final audit report will contain all classified deficiencies and all proposed actions of the auditee. As such, it will provide a detailed overview of the state of compliance of the auditee. The final audit report will not contain a final conclusion about approval or rejection of the auditee. Within three months a signed copy of the audit report is provided to the Customer. The original audit report will be archived by Lab Ofichem for 5 years. 4. Audit Follow Up The Customer is responsible to review the audit report including the proposed actions of the auditee. In case the proposed actions of the auditee are not considered to be sufficient by the Customer, the auditor will communicate this to the auditee and keep the Customer informed about follow up. The Customer is responsible for the final conclusion about approval or rejection of the auditee. 5. Confidentiality Lab Ofichem undertakes not to disclose any specific information related to the Customer. The audit report and other formal correspondence related to the audit execution is confidential. The Customer and Lab Ofichem agree that this confidential information is treated in the utmost and strictest confidence and assures that none of such confidential information is brought to the attention of third parties, unless both parties agree to share the information. The Customer agrees not to use the confidential information for activities that are in competition with the activities of the auditee(s). Lab Ofichem will maintain a secrecy agreement with the auditee. The Customer acknowledges that the confidential information may possess a special, unique and extraordinary character that would not be adequately compensated by money. The Customer agrees that in the event of use of the information in breach of its obligation in addition to legal and equitable rights and remedies, Lab Ofichem shall have the right to obtain temporary or permanent injunctions against such prohibited disclosure or use.
14 Lab Ofichem B.V. Pag.: 14 / 14 Date: Version: 02 Status: geldig 6. Liability 1. Lab Ofichem shall be held liable in causes to the Customer during the implementation of the Agreement only to the extent that they are the result of gross negligence. In case that Lab Ofichem shall be held liable the extent is limited to the costs of the audit(s). 2. Lab Ofichem shall not be held liable for claims by the Customer regarding insufficient performance by the Auditor. 3. Lab Ofichem shall not be held liable for unsuccessful inspections by authorities after having been audited under this agreement. 4. Lab Ofichem shall not be held liable in the case where participating companies are taking measures leading to any kind of financial impact on the Customer. 7. Copyright The copyright of the audit report will be shared by Lab Ofichem and the Customer. Any requests to pass on the audit report to subsequent Third Parties should be made to the other party. Written agreement will be required from the other party before the audit report may be issued to a subsequent third party. Copies of the audit report may be shown on request to European Member State Inspectors during inspection of the Medicinal Product Manufacturers. 8. Written form All modifications and amendments to this offer are only effective if they are agreed upon by the parties involved in writing. 9. Legal venue and applicable law Legal venue for any disputes shall be Ter Apel. The laws of the Netherlands are applicable. 10. Salvatory clause Should any of the above provisions in this Agreement be invalid this shall not impair the validity of this Agreement. It is to be substituted by the provisions coming closest to the intention of both parties which has to be laid down in writing. 11. Term This agreement shall come into force at the latest date of signing. The present agreement may be terminated upon written notice by one of the parties. The obligations under the section of confidentiality of this agreement shall remain in effect for ten (10) years from the date thereof. Place, date and signature of the Customer Place, date and signature of Lab Ofichem
The APIC Audit Programme Standardised Cost APIC-certified GMP Compliance A Third Party Audit Programme for API Manufactureres An Initiative of APIC in co-operation with CONCEPT HEIDELBERG A sector group
Audit Report in the framework of the APIC Audit Programme Company Location Address Country Subject of Audit Audit Date Auditor (lead) Co-Auditor(s) Participants Signature of Auditor(s) Lead Auditor Co-Auditor
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
GHTF/SG4/N28R4:2008 FINAL DOCUMENT Title: Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Authoring Group: GHTF Study Group 4 Endorsed by: The Global Harmonization
The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute
January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use
Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
Standard conditions of purchase 1 OFFER AND ACCEPTANCE 2 PROPERTY, RISK & DELIVERY 3 PRICES & RATES The Supplier shall provide all Goods and Services in accordance with the terms and conditions set out
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
Rules for Operators TABLE OF CONTENTS 1. Application for certification and FAMI QS associate membership...2 2. Assessment of operators...3 2.1. Audit planning...3 2.2. Frequency of audits and re certification...5
Frequently Asked Questions Unannounced audits for manufacturers of CE-marked medical devices 720 DM 0701-53a Rev 1 2014/10/02 What is an unannounced audit?... 6 Are unannounced audits part of a new requirement?...
Conditions of Offer A1 The offer documents comprise the offer form, letter of invitation to offer (if any), these Conditions of Offer and Conditions of Contract (Works & Services), the Working with Queensland
Safeguarding public health New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01) Tony Orme, Senior GDP Inspector Inspection, Enforcement and Standards Division
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 3 October 2014 EMA/572454/2014 Rev 17 Compliance and Inspection Compilation of Community
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
Insurer audit manual Disclaimer This publication may contain work health and safety and workers compensation information. It may include some of your obligations under the various legislations that WorkCover
SUPPLEMENTARY INTERNAL RULES IMPLEMENTING REGULATION (EC) N 45/2001 IN RELATION TO THE DATA PROTECTION OFFICER 10 September 2009 page 1 / 8 SUPPLEMENTARY INTERNAL RULES IMPLEMENTING REGULATION (EC) N 45/2001
Revision note: The previous report contained a combined use for the compliance report and interim compliance report. These have now been separated and renamed as, Pre-inspection Compliance Report and Interim
The European Pharmacopoeia and certificates of suitability (CEP) Your Logo Andrew McMath Ph.D. European Directorate for the Quality of Medicines (EDQM) Presented by: Andrew McMath Scientific Officer, EDQM
[Standard data protection [agreement/clauses] for the transfer of Personal Data from the University of Edinburgh (as Data Controller) to a Data Processor within the European Economic Area ] In this Agreement:-
Certification Scheme Y03 Compliance Management Systems ISO 19600 ONR 192050 Issue V2.1:2015-01-08 Austrian Standards plus GmbH Dr. Peter Jonas Heinestraße 38 A-1020 Vienna, Austria E-Mail: firstname.lastname@example.org
Feed Safety Incident and Crisis Management Procedure for EFISC, operators and CB s Version 1.0 final Date : March 2014 EFISC Feed Safety Incident and Crisis Management Procedure version 1.0, March 2014
JRI S STANDARD TERMS OF PURCHASE 1. INTERPRETATION 1.1 Definitions. In these Conditions, the following definitions apply: Business Day: a day (other than a Saturday, Sunday or public holiday) when banks
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry Version March 2015 QUESTIONS
Unofficial translation Riga, 11 November 2011 Regulation No. 246 (Minutes No. 43 of the meeting of the Board of the Financial and Capital Market Commission, item 8) Regulation for Establishing the Internal
Market withdrawal and suspension of marketing authorisation of medicinal product due to good manufacturing practice noncompliance in India C-269/13 Acino AG vs. European Commission, LS&R 885 Citeersuggestie:
1 AIRBUS GROUP BINDING CORPORATE RULES 2 Introduction The Binding Corporate Rules (hereinafter BCRs ) of the Airbus Group finalize the Airbus Group s provisions on the protection of Personal Data. These
CONSULTANT AGREEMENT THIS CONSULTANT S AGREEMENT (the Agreement ) is effective this day of, 2011, by and between the TOWN OF UNIVERSITY PARK (the Town ), a municipal corporation of the State of Maryland,
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL
General Rules for the certification of Management Systems Effective from 19/11/2015 RINA Via Corsica 12 16128 Genova - Italy tel. +39 010 53851 fax +39 010 5351000 website : www.rina.org Technical rules
Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations
82 GUIDANCE ON WHOLESALE DISTRIBUTION PRACTICE AND BROKERING Qualification of Customers and Suppliers 112 Qualification of suppliers 113 Compliance with GDP 113 Routine re-qualification 114 Due diligence
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group email@example.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
E-INVOICE AGREEMENT TERMS 11.06.2015 1 Definitions 1.1 Invoices File means a dataset containing e-invoices which is sent to the Bank by the Service Provider. 1.2 Invoice Requirements means the format requirements
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
Speakers: Dr Afshin Hosseiny Chair of the ECA Expert Working Group on GDP, Tabriz Consulting Comply with the new EU GDP Guideline Dr Martin Egger Pharmaserv Dr Daniel Müller GMP/GDP Inspector All participants
GUIDE TO IMPLEMENTING A REGULATORY FOOD SAFETY AUDITOR SYSTEM FEBRUARY 2016 2 Contents Introduction... 4 Scope and objectives... 5 Scope... 5 Objectives... 5 Responsibilities... 5 The role of the licensee
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
TOTAL QUALITY MANAGEMENT II Chapter 13: QUALITY AUDIT Dr. Shyamal Gomes Introduction: The term audit was defined in the 16th Century as the official examination of the accounts with verification by reference
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
Supply Chain Challenges and Risk Management Presented by Steve Williams Director SeerPharma P/L 21 st April 2009 PDA April 09 SW 1 Supply Chain - Some Useful Guidance cgmp Annex 8 cgmp Chapter 7 ICH Q7
MINISTRY OF ENVIRONMENT AND ENERGY DANISH ENVIRONMENTAL PROTECTION AGENCY Translation LK April 1996 CONSOLIDATED ACT FROM THE MINISTRY OF ENVIRONMENT AND ENERGY NO. 21 OF JANUARY 16, 1996 ON CHEMICAL SUBSTANCES
Recommendations for companies planning to use Cloud computing services From a legal standpoint, CNIL finds that Cloud computing raises a number of difficulties with regard to compliance with the legislation
IVT 9 th Annual Conference Change Control Change Control A Key Element of a Quality System Jerry Lanese Ph.D. CMC The Lanese Group, Inc. 2011 The Lanese Group 1 Will discuss A Quality System What is it
This form may not be modified without prior approval from the Department of Justice. Delete this header in execution (signature) version of agreement. HIPAA BUSINESS ASSOCIATE AGREEMENT This Business Associate
Guide to Good Distribution Practice of Medicinal Products for Human Use IA-G0046-2 10 APRIL 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
Site visit inspection report on compliance with HTA minimum standards London School of Hygiene & Tropical Medicine HTA licensing number 12066 Licensed under the Human Tissue Act 2004 for the storage of
GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme Contents 1. Why good documentation is essential? 2. What constitutes
Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting
Regulations for certification of quality management systems 00 24/04/2013 Annulla e sostituisce il documento Regulations for certification of quality management systems in rev. 14 SG DIR AD Rev. Data Descrizione
EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond 14 th International Conference of Drug Regulatory Authorities Pre-ICDRA Meeting Dr Susanne Keitel European Directorate
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist
Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and
General Terms of Public Procurement in Service Contracts January 2015 Contents Introduction...3 Issues to be observed in applying...5 General Terms of Public Procurement in Service Contracts ()...9 1 Definitions...9
Private Health Insurance Code of Conduct July 2014: Version 5 CONTENTS PART A: GENERAL 1 1. INTRODUCTION 1 1.1 Introduction 1 1.2 Compliance 1 2. OUR COMMITMENT UNDER THE CODE 2 3. PRIVATE HEALTH INSURANCE
Compliance Audit Handbook This Compliance Audit Handbook has been produced by the Compliance and Assurance Section of the Department of Environment and Conservation NSW (DEC). For technical information
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
Basic Rules of Issuing Invoices and Receipts 2014 Most requirements pertaining to invoicing are contained in Act CXXVII of 2007 on Value Added Tax (hereinafter: VAT Act) and the decrees issued on the basis
General Rules for the Certification of Management Systems Code: RG Drafted on: 1 April 2012 Effective from: 1 October 2012 TABLE OF CONTENTS CHAPTER TITLE PAGE CHAPTER 1 GENERAL 3 CHAPTER 2 REFERENCE STANDARD
TS004(COS)v01 The certification process for COSMOS standard Standard in force available on www.cosmos-standard.org or sent on request. 1 Contents I. When to apply... 3 II. The different steps in the certification
UBS Electronic Trading Agreement Global Markets Version: 1.1 November 2014 I. UBS ELECTRONIC TRADING AGREEMENT 1.1 UBS Limited ( UBSL ) provides an electronic trading service, which enables certain clients
[This translation is provided for guidance. The governing text is the Arabic text.] Form of Consultancy Engineering Services Contract (Supervision) Section One Contract - Basic Document It has been agreed
Ordinance on Specialised Waste Management Companies (Entsorgungsfachbetriebeverordnung - EfbV) *) of 10 September 1996 The Federal Government, having heard the parties concerned, and pursuant to Article
THE BUDAPEST STOCK EXCHANGE LTD. REGULATIONS ON THE USE OF REMOTE TRADING Date and reference no. of approval/modification resolutions by the Board of Directors: Date and reference no. of approval by Supervisory
EXAM PREPARATION GUIDE PECB Certified ISO 9001 Lead Auditor The objective of the Certified ISO 9001 Lead Auditor examination is to ensure that the candidate possesses the needed expertise to audit a Quality
(1987) Guidelines for the Acceptance of Manufacturer's Quality Assurance Systems for Welding Consumables 1. General 1.1 Introduction 1.1.1 The present guidelines are to serve as a supplement to the IACS
South Dakota Parental Rights and Procedural Safeguards Special Education Programs Revised July 2011 Prior Written Notice... 1 Definition of Parental Consent... 3 Definition of a Parent... 3 Parental Consent...
1. DEFINITIONS In these terms of engagement the following definitions apply:- NP The Client The Company The Contractor The Assignment The Terms means Nationwide People Limited. means the person, firm or
Translation GENERAL TERMS AND CONDITIONS FOR THE SUPPLY OF GRAPHIC PRODUCTS 2010 (ALG 10) Standard terms and conditions prepared by the Swedish Graphic Companies Federation (Grafiska Företagens Förbund),
Date(s) of Evaluation: CHECKLIST ISO/IEC 17021:2011 Conformity Assessment Requirements for Bodies Providing Audit and Certification of Management Systems Assessor(s) & Observer(s): Organization: Area/Field
Kingdom of the Netherlands GENERAL GOVERNMENT PURCHASING CONDITIONS 2014 (ARIV 2014) Adopted by order of the Prime Minister, Minister of General Affairs, of 26 March 2014, no. 3132081 I General Article